¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-09-23

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-09-23
±³À°ÀÏÀÚ : 2023-09-23

±³À°Àå¼Ò : ¼­¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°­´ç

±³À°ÁÖÁ¦ : 2023 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸¸¼º°ñ¼ö¼º¹éÇ÷º´¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kamslor.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀÎ : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 40ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í Àü¹®ÀÇ 50,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 09:30~10:05 Third-line treatment for CML(chronic myeloid leukemia) ÇÑÀçÁØ(°æÈñÀÇ´ë)

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 10:05~10:40 Treatment in advanced phase (AP/BC) of CML(chronic myeloid leukemia) ±è°æÇÏ(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 11:00~11:15 ASTER-P ¹Ú¼º¿ì(°æ»óÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 11:15~11:30 ASTER-A ¾öÁöÀº(ÇѾçÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 11:30~11:45 NGS( next generation sequencing) for ABL1 mutation ½Å»õ¾Ï(¿¬¼¼ÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 11:45~12:00 HBV(hepatitis B virus) prophylaxis in TKI-treated CML(chronic myeloid leukemia) ÀÌÀ¯Áø(¿ï»êÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 13:00~13:15 Ponatinib dose optimization ÀÌÁ¤¿Á(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 13:15~13:30 Dasatinib dose optimization ±è»ó¾Æ(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 13:30~13:45 Imatinib as 1st line therapy in very elderly CML(chronic myeloid leukemia)) patients Á¶ÁøÇö(ÀÎÇÏÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 13:45~14:00 Immune effect on TFR(total fertility rate ) ÃÖÀ±¼®(¾ÆÁÖÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 14:00~14:15 Nilotinib dose optimization ¹ÚÇö°æ(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 14:15~14:30 Asciminib as salvage therapy in real-world CML(chronic myeloid leukemia))practice ÃÖÀºÁö(¿ï»êÀÇ´ë )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-09-23""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û °ñ´Ù°øÁõ Áø´Ü ¹× Ä¡·á A to Z : 2023-09-23
´ÙÀ½±Û ´ëÇѵΰæºÎÁ¾¾çÇÐȸ 2023³â Á¦ 4ȸ µÎ°æºÎ ¿¬±¸Æ÷·³ : 2023-09-23
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 8 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 11 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 12 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 10 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 11 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 5 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 3 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 5 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 5 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 5 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 3 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 11 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 4 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 8 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 5 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷